# DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction

Study · id `cardio:ct-nct05764057` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05764057](<https://clinicaltrials.gov/study/NCT05764057>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05764057

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 450 participants.

## Technical summary

Registry record NCT05764057. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2026-10-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT05764057, source copy `cardio:ctgov-nct05764057-2025-12-19`, retrieved 2026-10-26)
- Started: 2023-06-12 (actual) (ClinicalTrials.gov record NCT05764057, source copy `cardio:ctgov-nct05764057-2025-12-19`, retrieved 2026-10-26)
- Primary completion: 2026-10-12 (anticipated) (ClinicalTrials.gov record NCT05764057, source copy `cardio:ctgov-nct05764057-2025-12-19`, retrieved 2026-10-26)
- Completion: 2026-10-12 (anticipated) (ClinicalTrials.gov record NCT05764057, source copy `cardio:ctgov-nct05764057-2025-12-19`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT05764057, source copy `cardio:ctgov-nct05764057-2025-12-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05764057-2025-12-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
- Acronym: DAPAPROTECTOR
- Condition: AMI
- Condition: STEMI
- Condition: NSTEMI
- Condition: Left Ventricular Dysfunction
- Intervention (Drug): Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- Intervention (Drug): Placebo comparator
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: a0e18264eaa6c92877ae9c8c5ea55ad74f197dd294a9a7f8414890f19b6e0e65
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
